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in vitro dissolution and permeability
A B S T R A C T
The aim of this work was to carry out preliminary experiments for preparation of levodopa (LEVO)-containing
intranasal powder. The experiments were designed according to the Quality by Design (QbD) concept. Based on
prior risk assessment, LEVO and chitosan (CH) or sodium hyaluronate (HA) as mucoadhesive matrix formers
were co-milled using planetary ball mill to prepare microparticles as drug delivery systems. The rotation speed,
the milling time and the drug-additive ratio were evaluated to be the most relevant milling factors - as a result of
the initial risk assessment; which were set according to a factorial design. The eﬀects of critical process para-
meters and excipients were investigated on the particle size and surface characteristics of products, and on the
crystallinity, in vitro dissolution and permeability of LEVO. Milling in the presence of higher amount of HA
resulted in smaller average particle size of powders (D50=13.068 μm) and higher initial dissolution and per-
meation of LEVO compared to CH-containing formulations (D50=21.667 μm).
1. Introduction
Parkinson's disease (PD) is a progressive neurodegenerative disorder
of the dopaminergic system in the straitum with decreased dopamine in
the central nervous system which causes motor dysfunction. There are 3
speciﬁed dopaminergic complications: wearing oﬀ, dyskinesias, or on-
oﬀ ﬂuctuations (Chun et al., 2011; Parkinson Study Group, 2000). Its'
worldwide prevalence reaches 1–2% among the people over the age of
50, and it has no gender preference (Goole and Amighi, 2009). LEVO is
a polar, water soluble drug (5mg/ml at 20 °C) (Chi et al., 2017) which
oxidizes and darkens rapidly in the presence of moisture (Drugbank,
web reference). It is the most commonly used medication in treating
PD.
Oral tablets of LEVO are available usually in combination with
decarboxylase inhibitors, e.g. 100mg LEVO with 25mg carbidopa. For
sustained release 200mg LEVO is combined with 50mg carbidopa,
allowing reduction of the dosing frequency. Only 1% of the orally ap-
plied dose reaches the central nervous system (CNS) (Marsili et al.,
2017), therefore intranasal application of LEVO is a new approach for
the prevention or for rapid treatment of muscle cramps (Kang et al.,
2009). Thanks to the well vascularised submucosa it can be a solution
for the fast absorption of drug to reach the systemic blood circulation
(“nose-to-blood” transport) (Sipos et al., 2010; Sandri et al., 2015) or
through the axonal transport (“nose-to-brain”) (Ong et al., 2014) di-
rectly the brain tissues reducing systemic exposure (Kürti et al., 2013;
Gieszinger et al., 2017). Although nasal delivery of drugs avoids the
hepatic ﬁrst-pass metabolism, the enzymatic barrier of the nasal mu-
cosa creates a pseudo-ﬁrst-pass eﬀect (e.g. cytochrome P-450, pepti-
dase, protease). The usage of enzyme inhibitors (e.g. 1‑aminobenzo-
triazole, bile salts) may improve absorption of drugs (Sarkar, 1992;
Llinás et al., 2004).
LEVO-containing powder has been recognized as eﬃcient nasal
delivery system oﬀering numerous advantages over liquid formulations,
such as avoidance of preservatives, improved formulation stability, and
prolonged contact with the mucosa (Filipović-Grčić and Hafner, 2010).
There are data on the application of LEVO in nasal formulations: nasal
delivery systems prepared using maleic acid solution containing 2‑hy-
droxypropyl‑β‑cyclodextrin, administered in solution form were in-
vestigated, where the absolute bioavailability of drug was higher in
case of nasal route, comparing with oral administration using data of
intravenous injection (Kim et al., 2009). Methyl ester of LEVO was
mixed with additives in order to prepare formulations with raised drug
bioavailability (Chun et al., 2011). The permeability of its solution and
microparticulate form was compared, where the microsized drug
powder proved to be more eﬃcient (Vasa et al., 2017).
By the design of intranasal powder drug delivery systems, it is
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important to consider some requirements for instance particles size
(from 5 to 40 μm) and high adhesion (Billotte et al., 2003). To set the
proper particle size, milling is an often applied method. For production
of microparticles, dry milling is a commonly used technique (Liu et al.,
2014). Beyond the optimization of particle size according to the re-
quirements of nasal dosage forms, the bioavailability of active phar-
maceutical ingredients (APIs) can be improved after milling, increasing
the rate of dissolution of the drug (Noyes and Whitney, 1897). The
limitation of short residence time of the formulations in the nose and
poor bioavailability of hydrophilic drugs could be overcome by its in-
clusion to the matrix system of bioadhesive polymers (cellulose deri-
vates, carbomers, lectins, chitosans (CH), sodium hyaluronate (HA)),
forming microparticles (Rashid, 2014; Pathak, 2011; Anand et al.,
2012; Caramella et al., 2016). CH is a positively charged linear poly-
saccharide that is bioadhesive and able to interact strongly with the
nasal epithelial cells and the overlaying mucus layer thereby providing
a longer contact time for drug transport. CH has absorption enhancing
eﬀect which is caused by opening of the intercellular tight junctions,
thereby favouring the paracellular transport of macromolecular drugs
(Elviri et al., 2015; Casettari and Illum, 2014; Van der Lubben et al.,
2001). HA is a natural anionic polysaccharide with excellent mu-
coadhesive capacity (Liao et al., 2005), high biocompatibility and low
immunogenicity (Ding et al., 2012). Besides its mucoadhesive proper-
ties, it may enhance the absorption of drugs and proteins with small
molecule weight via the mucosal tissues (Lim et al., 2000).
The QbD approach is a risk and knowledge based quality manage-
ment method, where the focus is on the profound preliminary target
product design and the practical experiments are based on the results of
the Risk Assessment(s) (RA) performed (Yu, 2008). The QbD is a hol-
istic and systemic way of improvements and its application is re-
commended by the authorities from the very ﬁrst step of the pharma-
ceutical developments. The whole method and the elements of the QbD
is described in the guidelines of the International Council on Harmo-
nization (ICH) (ICH Q8R2, ICH Q9, ICH Q10) (ICH. Pharmaceutical
Development Q8, 2009; ICH. Quality Risk Management Q9, 2005; Ich.
ICH Q10 Pharmaceutical Quality Systems, 2009). In a QbD-based de-
velopment, the ﬁrst step is the prior deﬁnition of the Quality Target
Product Proﬁle (QTPP) which contains the essential parameters from
the point of view of the patient and the clinical setting. It is a pro-
spective summary of the quality characteristics of the product that
ideally will be achieved. The next step is the selection of the parameters
that inﬂuence the QTPPs critically. These are the Critical Quality At-
tributes (CQAs) related to the safety and eﬃcacy of the product, Critical
Material Attributes (CMAs) and the Critical Process Parameters (CPPs)
the related to the selected production method. The key element of a
QbD-guided development is the RA (it can be initial, recurrent/updated
or ﬁnalized) as it is resulted in ranked CQAs and CPPs by their critical
eﬀect on the targeted product quality. Then, the Design of Experiments
(DoE) can be set up based on the results of the RA, which means that the
practical experiments are planned and executed according to the most
relevant inﬂuencing factors (CQAs, CPPs). In the following step the
determination of the product's Design Space (DS) can be performed. The
DS has remarkable regulatory beneﬁts as production parameter mod-
iﬁcations in the DS do not require modiﬁcations in submission. The
following steps of the QbD method are the improvement of the Control
Strategy and planning of the Continuous Improvement which have re-
levance from the pharmaceutical industry perspective (Yu et al., 2014).
The QbD and RA-based development and screening has several
advantages, as the experiments in practice could be more eﬀective and
it can be used successfully even in the early development of pharma-
ceutical products (Pallagi et al., 2015; Karimi et al., 2016; Pallagi et al.,
2016; Gieszinger et al., 2017).
The aim of this study was to design and formulate LEVO containing
mucoadhesive intranasal powder for controlled drug delivery with a
fast initial release (within 15min). Microparticles were prepared by
means of the dry milling method, based on the QbD approach. Process
parameters of milling were determined according to the factorial design
plan. In order to ensure the deposition of the product in the nasal
cavity, the required particle size was larger than 10 μm (EMA, web
reference). Diﬀerent additives, such as CH and HA were used and
compared as mucoadhesive polymers for incorporation of LEVO. The
morphology, the crystal-to-amorphous transformation (because of the
potential eﬀect on the dissolution rate), the polarity and the in vitro
dissolution/permeability of milled products were determined and
evaluated.
2. Materials and methods
2.1. Materials
LEVO (3,4‑dihydroxy‑L‑phenylalanine) was obtained from
Hungaropharma Ltd. (Hungary). Chitosan (CH)
(Mw=3800–20,000 Da), an insoluble additive in aqueous solutions at
pH > 6.0 (Sogias et al., 2010) was purchased from Sigma-Aldrich
(Hungary). Sodium hyaluronate (HA) (Mw=1400 kDa), a water-so-
luble polymer (46.6mg/ml) (Drugbank, web reference) was obtained as
a gift from Gedeon Richter Plc. (Budapest, Hungary).
2.2. Initial risk assessment and knowledge space development
To perform the QbD-based initial RA, the ﬁrst step was the de-
termination of the QTPP of the target product. The CQAs and the CPPs
of the selected production method were identiﬁed as the second step. A
primary knowledge space development (Pallagi et al., 2016) was made
as part of the QbD methodology and an Ishikawa diagram (Tague,
2005; Ishikawa, 1985) was set up. The LeanQbD® software (QbD Works
LLC, Fremont, CA, USA, www.qbdworks.com) was used for the RA
procedure. The interdependence rating among the QTPPs and CQAs and
also among the CQAs and CPPs were evaluated as the ﬁrst step of the
RA. A three-level scale was used to describe the relation between the
parameters: “high” (H), “medium” (M) or “low” (L). Then, a risk oc-
currence rating (or probability rating step) was made; where a 0–10
scale was used for estimation of the CPPs where the values were as-
signed to a similar H/M/L ranking structure by the software. As the
output of the RA evaluation, Pareto diagrams were generated pre-
senting the numeric data and the ranking of the CQAs and CPPs ac-
cording to their potential impact on product quality.
2.3. Screening factorial design of experiments
The design of experiments was performed according to the
“screening factorial design”. The factors were selected based on the
results of the RA, where the CQAs and CPPs being the most critical or
highest impact on the ﬁnal product quality were selected. These factors
were: the drug-additive ratio, the milling time and the milling (rota-
tion) speed. Investigations were completed containing CH and HA as
excipients, where the variation of the + and− level of the factors were
applied. The levels used were the following: drug-additive ratio: 0.5
(−) and 1 (+), the milling time: 60min (−) and 90min (+), the
milling speed: 300 rpm (−) and 400 (+) rpm. The 8–8 products were
also prepared in each cases and the particle size/particle size distribu-
tion, the structure (crystallinity, measured by XRPD) and the in vitro
features (dissolution and permeability) of the samples were measured
as the key parameters representing the samples.
2.4. Sample preparation
LEVO and additives (CH or HA) were homogenized in a Turbula
mixer (Turbula System Schatz; Willy A. Bachofen AG Maschinenfabrik,
Basel, Switzerland) using 60 rpm for 10min. After mixing, the samples
were placed into the milling chamber of a planetary ball mill (Retsch
PM 100; Retsch GmbH, Haan, Germany), where milling was occurred
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with milling balls, 10mm in diameter according to the response factors
of factorial design, as particle size, crystallinity index and in vitro drug
release (amount of dissolved and permeated drug) (Table 1). Physico-
chemical investigations of prepared products were carried out in order
to facilitate the understanding of its in vitro behaviours.
2.5. Determination of particle size of products
Particle size of LEVO containing products was measured by laser
diﬀraction. The particle size determination was performed by laser
scattering using Malvern (Malvern Mastersizer Scirocco 2000, Malvern
Instruments Ltd., Worcestershire, UK). Air was used as the dispersion
medium for the microparticles from the entrance to the sample cell. The
particle size was characterized by the average particle size (D50) value
and compared with the requirements (10–40 μm) of European
Medicines Agency Inspections (EMA) (EMA, web reference, Billotte
et al., 2003).
2.6. X-ray powder diﬀraction (XRPD)
The structural characterization (the eﬀect of the preparation pro-
cedure on the particle characters) was accomplished by an X-ray
powder diﬀraction BRUKER D8 Advance X-ray diﬀractometer (Bruker
AXS GmbH, Karlsruhe, Germany). The amorphous or crystalline char-
acter of the drug could reasoned the further in vitro investigations.
Measurements were carried out with a slit-detector Cu K λI radiation
(λ=1.5406 Å) source. The products were scanned at 40 kV and 40mA
and the angular range was 3°–40° 2θ, at a step time of 0.1 s and a step
size of 0.007°. The crystallinity was determined semi-quantitatively via
the mean of the decrease of the total area beneath the curve of 2
characteristic peaks (at 14.1 and 21.180 2θ) compared to the physical
mixture (PM). The crystallinity index (xc) values were calculated based










2.7. Image analysis (SEM)
The products were visualized by using SEM (Hitachi S4700, Hitachi
Scientiﬁc Ltd., Tokyo, Japan). The samples were sputter-coated with
gold–palladium under an argon atmosphere, applying a gold sputter
module in a high-vacuum evaporator, and they were investigated at
15 kV and 10 μA. The air pressure was 1.3–13MPa.
2.8. Drug content determination
For the determination of drug content in the milled products 5mg
LEVO-containing samples were dispersed in 50ml phosphate buﬀer
(PBS) pH 5.60. For the preparation of PBS dipotassium hydrogen
phosphate and potassium dihydrogen phosphate were used. After 2 h of
stirring with magnetic stirrer, the samples were vortexed, ﬁltered and
the amount of LEVO was determined using spectrophotometry (Unicam
UV/VIS Spectrophotometer) at 280 nm.






where the “Drug content theoretical” is 5 mg LEVO, and the “Drug
content experimental” is the spectrophotometrically measured eﬀective
amount of LEVO in the samples.
2.9. Contact angle measurements
The contact angle (θ) was measured by means of the sessile drop
technique, using an OCA 20 Optical Contact Angle Measuring System
(Dataphysics, Filderstadt, Germany) and the method of Wu. 0.10 g of
milled products was compressed under a pressure of 1 ton by a Specac
hydraulic press (Specac Inc., USA). The wetting angles of the pressings
were determined after dropping onto the surface of the liquid agents,
which were bi-distilled water (interfacial tension of polar component
(γp)= 50.2 mN/m, interfacial tension of disperse component
(γd)= 22.6mN/m) and diiodomethane (γp= 1.8mN/m, γd= 49mN/
m). Polarity percentage was calculated from the interfacial tension of









2.10. Fourier transform infrared (FT-IR) spectroscopy
FT-IR spectra were recorded with a Bio-Rad Digilab Division FTS-
65A/896 FTIR spectrometer (Bio-Rad Digilab Division FTS-65A/869,
Philadelphia, USA) between 4000 and 400 cm-1, at an optical resolu-
tion of 4 cm-1, operating conditions: Harrick's Meridian SplitPea single
reﬂection, diamond, ATR accessory. Thermo Scientiﬁc GRAMS/AI Suite
software (Thermo Fisher Scienciﬁc Inc., Waltham, USA) was used for
the spectral analysis.
2.11. In vitro dissolution test
The dissolution test was carried out under nasal conditions at 30 °C.
The medium was 50ml PBS of pH 5.60, in which 0.25 g LEVO-con-
taining products were put. The medium was stirred with magnetic
stirrer at 50 rpm, and the sampling was performed up to 60min. After
ﬁltration, the drug contents of the aliquots were determined using
spectrophotometer (Unicam UV–VIS Spectrophotometer) at 280 nm.
The measurements were performed in triplicate. The in vitro drug re-
lease data of products were evaluated kinetically using various math-
ematical models like zero order, ﬁrst order, Higuchi, and Korsmeyer-
Peppas model (Garg et al., 2017).
2.12. In vitro diﬀusion study
In vitro permeability studies were carried out on a modiﬁed hor-
izontal Side-Bi-Side™ cell model (Grown Glass, New York). The two
chambers were divided by an impregnated (with isopropyl myristate)
artiﬁcial membrane (PALL Metricel membrane, 0.45 μm pore size). The
volumes of the donor and the acceptor phases were the same (3.0ml)
with a 0.69 cm2 diﬀusion area. PBS of pH 5.60 was applied as donor
phase, in which 0.25 g LEVO-containing samples were inserted. PBS of
pH 7.40, the aqueous solution of the mixture of sodium chloride, po-
tassium chloride, disodium hydrogen phosphate and potassium dihy-
drogen phosphate, was used as an acceptor phase. The temperature of
the phases was 30 °C (Thermo Haake C10-P5, Sigma, Aldrich Co.) and
the rotation speed of the stir-bars was set to 100 rpm. Aliquots (2.0 ml)
were taken from the acceptor phase by pipette and were replaced with
fresh receiving medium at 5, 10, 15 and 60min of the investigation.
The amount of LEVO diﬀused was determined spectrophotometrically
(Unicam UV/VIS) at 280 nm; each sample was measured three times.
Table 1
Investigated parameters using a planetary ball mill.
Drug:additive ratio Time (min) Rotational speed (rpm)
1:1 60/90 300/400
1:0.5 60/90 300/400
Additives: CH and HA.
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3. Results and discussion
3.1. Knowledge space development and RA
As the result of the primary knowledge space development step an
Ishikawa (ﬁshbone) diagram was set up. This cause and eﬀect diagram
includes all the parameters which inﬂuence the desired LEVO-con-
taining powder product for nasal use (Fig. 1). The parameters were
ranked into four groups, namely, 1) material characteristics; 2) pro-
duction method; 3) product characteristics and 4) therapeutic ex-
pectations. This process gave a collection of preliminary knowledge and
information, which helped to design the whole development process
and to select the appropriate CQAs and CPPs of the procedure.
First of all, the QTPP was deﬁned describing the desired product
characteristics. In this case the QTPP includes the therapeutic indica-
tion, which was the therapy of the Parkinson's disease by using LEVO as
active agent, the required dosage form was a powder formula, for the
administration route the nasal administration was chosen, in order to
reach the systemic eﬀect easier and quicker than the conventional drug
applications, and to have a decreased dose of the API related to the per
os dose of the LEVO. For the same reason was also aimed to reach the
proper size range for the previously deﬁned aims. The limitation of the
nasal application is that the nasal mucosa secretion is renewed in every
10–15min. It caused, that the other element of the QTPP was the im-
mediate drug release of the aimed product for appropriate absorption
from the nasal cavity.
After determining the QTPP, the CQAs and the CPPs/CMAs were
also identiﬁed. The selected CQAs were the following: (1) wettability,
for nasal mucosa adhesion, linked to eﬃcacy, (2) the structure of the
API, aimed having a crystalline structure (3) the immediate drug re-
lease, linked to the nasal conditions, and related to eﬃcacy, (4) solu-
bility, as proper solubility is linked to eﬃcacy and safety, by the drug
release, and (7) product particle size, which has strong eﬀect on ab-
sorption in this case. To the CMAs/CPPs the milling speed (or rotation
speed), the milling time, the drug-additive ratio, and the initial particle
size of the API (as the single CMA) were enumerated.
The QTPPs next to the CQAs and the CMA/CPPs are marked in the
Fig. 2, which presents graphically the results of the interdependence
rating as part of the RA between the QTPP elements and CQAs one by
one (Fig. 2A), and also among the CQAs and CPPs/CMAs (Fig. 2B). The
Fig. 2 also presents the results of the initial RA, which is a prediction of
the relative eﬀect of the CQAs and the CPPs on the QTPPs. The CQAs
and CPPs/CMAs are presented in Pareto charts generated by the soft-
ware (Fig. 2C) showing the numeric data of the critical factors and their
ranking.
These RA results show, that the product particle size and the
structure of LEVO can be predicted to have the greatest eﬀect on the
quality of the targeted product among the CQAs, these are followed by
the drug release, solubility and wettability. The analog diagram shows
that among the CPPs, drug: additive ratio, API's initial particle size, the
milling time and the milling speed had to be expected to have the
highest inﬂuence on the quality of the aimed product. According to the
RA results, the further development (screening studies and product
preparation) focused on the selected CQAs and CPPs. The chosen factors
for screening design were the drug-additive ratio, the milling time and
the milling (rotation) speed, and the product particle size, the structure
and the in vitro permeability of the products were measured for sample
classiﬁcation.
3.2. Eﬀect of milling parameters on the products
According to the results of RA, the eﬀect of drug:additive ratio, the
milling time and the milling speed were investigated on the properties
of milled products, as long as the initial particle size of LEVO was
Fig. 1. Ishikawa, or cause and eﬀect diagram about the inﬂuencing parameters of L-Dopa containing powder formula for nasal use (abbreviations: API= active, SEM,
scanning electron microscopy; DSC, diﬀerential scanning calorimetry; XRPD, X-ray powder diﬀraction; GI, gastrointestinal; CNS, central nervous system).
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considered as a constant value.
3.2.1. Particle size and structural characteristics of products
Particle size of products was determined by using laser diﬀraction
method. As a preliminary experiments the drug and additives were
milled separately. Milling of additives resulted in its particle size re-
duction (CH: the average particle size decreased from 170.827 to
48.825 μm; HA: the D50 value reduced from 166.257 to 18.053 μm)
after 60min at 400 rpm. Milling of LEVO without additives resulted in
aggregation of drug particles increasing the milling time (D50 value
raised from 22.180 μm - after 60min - to 48.825 μm and after 90min to
75.969 μm). This can be explained by the increased cohesiveness of
particles (Fukunaka et al., 2005). After Turbula mixing of LEVO and
additives, physical mixtures (PMs) were produced, which had lower
particle size (Tables 2 and 3) than the raw polymers (D50 was
170.827 μm of CH and 166.257 μm of HA). During milling, the average
particle size of products decreased by increasing the milling time and
speed, and decreasing of the drug_additive ratio. The decrease was
more remarkable in the case of HA-containing samples comparing with
CH-containing products.
The XRPD pattern of LEVO in the PMs of LEVO_CH and LEVO_HA
demonstrated its crystalline structure, as expected. Milling resulted in
amorphization of LEVO. The presence of higher amount of additives
(1_1) was possible to retain the amorphous form of drug. In case of
lower drug_additive ratio (1_0.5), higher percent of drug remained
crystalline during milling in the presence of both additives. In case of
lower amount of HA remarkable amorphization was perceptible com-
paring with CH-containing samples (Tables 2 and 3).
Being aware of the advantages of low particle size and amorphous
form of drugs, samples with decreased particle size and the lowest
Fig. 2. Results of the interdependence ratings of the QTPP and CQAs (A) and CQAs –CPPs/CMAs (B) as well the Pareto charts of the CQAs and CPPs with calculated
numeric severity scores (C) generated by the RA software.
Abbreviations: QTPP, quality target product proﬁle; CQA, critical quality attribute; CPP, critical process parameter; RA, risk assessment; API, active pharmaceutical
ingredient; L, low; M, medium; H, high.
Table 2
The average particle size and the crystallinity index of CH-containing samples.
D50 (μm) Crystallinity index (%)
LEVO_CH_1_1_PM 133.444 ± 27.115 100
LEVO_CH_1_1_60_300 32.985 ± 1.578 17.85
LEVO_CH_1_1_90_300 27.195 ± 1.265 8.93
LEVO_CH_1_1_60_400 21.667 ± 0.970 5.95
LEVO_CH_1_1_90_400 20.904 ± 0.647 8.35
LEVO_CH_1_0.5_PM 86.530 ± 16.521 100
LEVO_CH_1_0.5_60_300 19.417 ± 0.412 71.204
LEVO_CH_1_0.5_90_300 15.816 ± 0.110 79.88
LEVO_CH_1_0.5_60_400 17.733 ± 0.318 36.125
LEVO_CH_1_0.5_90_400 16.392 ± 0.112 40.55
Table 3
The average particle size and the crystallinity index of HA-containing samples.
D50 (μm) Crystallinity index (%)
LEVO_HA_1_1_PM 102.152 ± 19.211 100
LEVO_HA_1_1_60_300 21.151 ± 0.691 7.95
LEVO_HA_1_1_90_300 10.032 ± 0.258 9.50
LEVO_HA_1_1_60_400 13.068 ± 0.390 5.02
LEVO_HA_1_1_90_400 10.641 ± 0.296 7.12
LEVO_HA_1_0.5_PM 41.641 ± 8.340 100
LEVO_HA_1_0.5_60_300 10.132 ± 0.478 24.90
LEVO_HA_1_0.5_90_300 10.906 ± 0.381 34.54
LEVO_HA_1_0.5_60_400 9.248 ± 0.212 20.32
LEVO_HA_1_0.5_90_400 9.819 ± 0.130 15.89
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crystallinity of LEVO were chosen to be subject to additional in-
vestigations in order to compare the eﬀect of additives. PMs, appertain
to them were used as references.
3.2.2. Morphology of the prepared products
The SEM images (Fig. 3) provided an indication of the morphology
of PMs and milled products (60min, 400 rpm). In case of PMs the
smaller, misaligned LEVO particles (D50≈ 22 μm) were located be-
tween the much bigger additive particles (approximately with 170 μm
average particle size). Thanks to the milling, the structure of polymers
deformed, reducing their particle size and modiﬁed the morphology.
LEVO particles were found on the surface of polymer microparticles.
3.2.3. Content of LEVO in the products
The drug content of PMs and milled samples were detected, which
was between 94.6 and 100.4%. According to these results, the homo-
genous distribution of materials was established.
3.2.4. Contact angle measurements
The nasal powders have a direct contact with the mucosa, therefore
the wettability of the products has an important inﬂuence on the dis-
solution rate and the drug release proﬁle. Wettability was characterized
by the contact angle of the liquid (water). A smaller contact angle in-
dicates a better wettability of the polymer, used as additive during
milling. Table 4 shows that there was no signiﬁcant diﬀerence between
the surface free energy (γ) and polarity values of polymers. However
the polarity value around 40–45% determined a hydrophil character in
every cases. According to these results it can be established that there
wasn't a signiﬁcant eﬀect of milling procedure and the type of polymer
on the polarity of the products.
3.2.5. In vitro dissolution
The in vitro dissolution test was achieved at the conditions of the
nasal cavity (pH 5.60). However, there was no signiﬁcant diﬀerence
between the polarity of samples, various dissolution rate of LEVO was
considerable in the presence of diﬀerent additives (Fig. 4). In order to
detect the interaction (e.g. salt formation between LEVO and additives
or electrostatic interaction between phosphate and amino groups of
CH) in the samples, FT-IR investigations were carried out, which proved
that no interaction between components were noticed, because there
were no changes in the characteristic bands, no shifting was detected.
The characteristic bands of LEVO were seen in all of the curves, at 1245,
1739, 3353, 3189, and 3035 cm−1. In the case of CH-containing sam-
ples lower dissolution rate and less dissolved amount of drug were
perceptible, which can be explained with the much higher viscosity of
CH-containing dispersion (η=2885.0 Pas) comparing with the HA-
solution (η=316.7 mPas). Keeping in the LEVO, CH reduced its dif-
fusion. Faster dissolution of drug was determined from the HA-con-
taining samples (LEVO_HA_1_1_60_400). Approximately 80% of LEVO
dissolved during 1 h in case of product. Sample milled with 400 rpm for
60min (drug_HA=1_1 ratio) revealed controlled drug release with a
fast initial dissolution within 15min, after then the slow release with
increasing drug concentration. The fast initial section can be explained
with rapid gelling of HA, forming supramolecular interaction between
its polymer chains and the phosphate salt (Krüger-Szabó et al., 2015),
and the small particle size and the most remarkable amorphization of
LEVO. To compare the detected drug concentration at 15min, we ob-
served 6–10 times higher amount by the HA-containing products, re-
ﬂected the increasing in the solubility also.
During the analyses of the kinetics of drug release the data was
evaluated by correlation coeﬃcient (R2). R values were used as the
criteria to choose the best model to describe drug release from the
Fig. 3. SEM pictures of PMs and milled products (A: LEVO_CH_1_1_PM; B: LEVO_CH_1_1_60_400; C: LEVO_HA_1_1_PM; D: LEVO_HA_1_1_60_400)
Abbreviations: SEM, scanning electron microscopy; PM, physical mixture; LEVO, levodopa; CH, chitosan; HA, sodium hyaluronate.
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milled products. The dissolved amount of LEVO from the CH-containing
samples was unacceptably low. In case of HA-products, the R2 (0.97 for
PM and 0.87 for milled product) obtained for ﬁtting the drug release
data to the Higuchi equation (Qt/Q∞=kHt1/2; Qt is the amount of drug
released at time t; k the release rate constant; Garg et al., 2017) in-
dicated that the drug release mechanism from this samples was diﬀu-
sion controlled by rapid gelling of HA. The higher R2 value shows a
better ﬁt, but the initial rapid dissolution of LEVO is lower than from
the milled product.
3.2.6. In vitro diﬀusion
Application of Side-Bi-Side™ model provided the continuous stirring
of the donor phase, thereby the homogeneous distribution of the nasal
dry powder formulations was ensured. Fig. 5 shows that LEVO per-
meated at highest rate (400 μg/cm2) from milled HA-containing pro-
duct. Rapid dissolution of amorphized LEVO particles provided a faster
diﬀusion and a higher drug concentration. In the case of LEVO_-
HA_1_1_PM sample and CH-containing products the permeation was
negligible, only around 10 μg/cm2 because, on the one hand the dis-
solution and permeation of crystalline drug was lower comparing with
amorphous form, on the other hand the presence of CH reduced the
diﬀusion of drug.
4. Conclusions
The aim of this research was to develop LEVO-containing drug de-
livery systems; to determine the main risks and also the critical quality
attributes; followed by the development of the control strategy in case
of intranasal powder formulation using dry milling, by means of the
QbD method. This work characterized the physicochemical properties
(particles size, crystalline structure, shape and polarity) of the nasal
powders and investigated the dissolution rate and diﬀusion through the
artiﬁcial membrane.
The performed initial RA resulted in the identiﬁcation of the factors
that mainly aﬀect the quality of the desired LEVO product for nasal use.
The results of the RA showed that among the CQAs, the particle size has
theoretically the highest eﬀect on the ﬁnal product quality and per-
formance and it is inﬂuenced the most by the milling time and milling
speed related to the production process. The RA based screening ex-
perimental design resulted in an eﬀective sample preparation step (8
samples prepared with CH as additive, and 8 samples prepared with
HA), where the focus was on the critical factors (a minimum (−) and a
maximum (+) level used in each case), thus led to an optimized con-
sumption of time, human and ﬁnancial sources during the development.
During our work LEVO-containing drug delivery systems were
produced. Because of the oxidation sensitivity of drug, nasal powder
was chosen as a formulation. Dry milling was applied in order to for-
mulate LEVO-containing microparticles in the presence of two diﬀerent
mucoadhesive additives (CH and HA). Our results showed that the
particle size of products suited the requirements (10–40 μm) (EMA, web
reference, Billotte et al., 2003). The presence of CH – resulting high
viscosity (η=2885.0 Pas) – kept in the LEVO and reduced its diﬀusion
from the intranasal formulation, therefore resulted in the poor dissolved
and permeated amount of drug. Products, which contained HA were
suggested for further development. Nasal powder, which contained
higher amount of HA (1_1), and was milled for 60min with 400 rpm
rotation speed, resulted in controlled drug release with a fast initial
dissolution within 15min (according to our aims), after then slow re-
lease with increasing concentration in time. The amount of drug, re-
leased in the ﬁrst 15min, was 3.15mg/ml, thanks to the rapid gelling of
HA and the small particle size (D50=13.068 μm) and the amorphi-
zation of LEVO.
Co-milling of LEVO with HA, as a mucoadhesive matrix former
agent, resulted in rapid, and sustained eﬀect at the same time.
Furthermore, higher dissolved and permeated amount of LEVO was
ensured compared to the PM. Being aware of the diﬃculties of the
therapy of PD, and possibilities and advantages of the nasal adminis-
tration route, our work can be a starting-point for further development
of an innovative nasal powder of LEVO for prevention or decrease the
muscle cramps in PD.
Table 4
Contact angles, surface free energies and polarities of the milled products.
θwater (°) θ diiodomethane (°) γp (mN/m) γ (mN/m) Polarity (%)
LEVO_CH_1_1_PM 10.3 ± 0.89 4.33 ± 1.57 36.05 81.77 44.09
LEVO_CH_1_1_60_400 11.33 ± 3.70 11.2 ± 2.28 36.12 81.07 44.55
LEVO_HA_1_1_PM 17.9 ± 1.82 8.1 ± 2.03 34.45 79.84 43.15
LEVO_HA_1_1_60_400 18.85 ± 2.16 8.53 ± 2.18 34.20 79.54 43.00
Fig. 4. In vitro dissolution of milled products.
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